NewsBite

AUDUSD0.6305
-0.0001 (-0.02%)-0.02%
S&P/ASX 2008,010.70
68.20 (0.86%)0.86%
All Ords8,234.40
67.70 (0.83%)0.83%
NZX 504,557.11
57.48 (1.28%)1.28%
Hang Seng23,360.26
16.01 (0.07%)0.07%
Nikkei37,890.15
109.61 (0.29%)0.29%
View all

ASX ends higher; Gold hits record of $US1944 an ounce

Advertisement

COVID-19 test volumes trigger Healius rebound

Medical centres and pathology group Healius says its pathology division has experienced a strong recovery in trading because of the sharp acceleration in the number of COVID-19 tests being carried out by various states, with robust trading expected to continue over the next few months.

The company said on Monday its pathology business was currently doing up to 16,000 tests per day, and in the coronavirus hotspot of Victoria was undertaking close to 50 per cent of the private COVID-19 tests in that state.

Healius is among the three largest pathology service providers in Australia, with Sonic Healthcare and Australian Clinical Labs also big players.

Healius runs a large pathology business which has rebounded strongly because of a sharp rise in the number of COVID-19 tests required.  Fairfax Media

The company said pathology testing generally in medical areas not related to COVID-19 had also been growing again as the economy gradually re-opened after the national lockdown in Australia from mid-March.

Healius chief executive Malcolm Parmenter pledged to regularly update the market because of the fast-moving situation across Australia in the battle against COVID-19.

"While our volumes are moving all the time and are difficult to predict, we are encouraged by the current strong trading levels in pathology, our largest business,'' Dr Parmenter said.

Read the full story at afr.com.

1 / 6

Latest In Equity markets

Fetching latest articles

Sponsored

Most Viewed In Markets

    Original URL: https://www.afr.com/markets/equity-markets/asx-to-drop-us-china-tensions-return-20200727-p55for